Cytodyn Inc
Change company Symbol lookup
Select an option...
CYDY Cytodyn Inc
IZEA IZEA Worldwide Inc
HAIIF Haitian International Holdings Ltd
PM Philip Morris International Inc
CCLP CSI Compressco LP
CBWTF Auxly Cannabis Group Inc
FGPR Ferrellgas Partners LP
PFE Pfizer Inc
MSFT Microsoft Corp
DNKN Dunkin' Brands Group Inc
Go

Health Care : Biotechnology |
Company profile

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.

Price
Delayed
$4.90
Day's Change
-0.074 (-1.49%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.08
Day's Low
4.70
Volume
(Light)

Today's volume of 2,777,554 shares is on pace to be much lighter than CYDY's 10-day average volume of 6,678,742 shares.

2,777,554

Important Update for CytoDyn Special Meeting of Stockholders

3:49 pm ET July 8, 2020 (Globe Newswire) Print

Change in Location of the Special Meeting to be held on July 22, 2020

Meeting Date: July 22, 2020

Meeting Time: 9:30 a.m. (Pacific Time)

Meeting Access: http://www.meetingcenter.io/285700571

Due to the emerging public health impact of the coronavirus outbreak (COVID-19) and to support the health and well-being of our employees, stockholders, and our community please note that the CytoDyn Inc. Special Meeting of Stockholders will be held on July 22, 2020 in virtual format only. In person attendance at the Special Meeting by stockholders will not be permitted.

To access the virtual meeting please click the Virtual Stockholder Meeting link. To login to the virtual meeting, you have two options: Join as a "Guest" or Join as a "Stockholder." If you join as a "Stockholder," you will be required to have a control number and password to login to the virtual meeting. The password for the meeting is CYDY2020.

If you were a stockholder as of the close of business on June 17, 2020 and have your control number, you may vote during the Special Meeting by following the instructions available on the meeting website during the meeting. For registered stockholders, the control number can be found on your proxy card or notice, or email you previously received.

If you hold your shares through an intermediary, such as a bank or broker, you must register in advance to attend the Special Meeting. To register you must submit proof of your proxy power (legal proxy) reflecting your CytoDyn Inc. holdings along with your name and email address to Computershare. Requests for registration must be labeled as "Legal Proxy" and be received no later than 5:00 p.m., Eastern Time, on July 17, 2020. You will receive a confirmation email from Computershare of your registration.

Requests for registration should be directed to Computershare at the following address:

By email:

Forward the email from your broker, or attach an image of your legal proxy, to legalproxy@computershare.com

If you do not have your control number, you may attend as a guest but will not have the option to vote your shares or ask questions at the virtual meeting.

Stockholders are reminded to vote their shares whether they plan to attend the virtual meeting or not. Stockholders may vote their shares in advance of the meeting by one of the methods described in CytoDyn's Proxy Statement filed with the SEC on June 22, 2020.

Please note that the proxy card included with the proxy materials previously distributed will not be updated to reflect the change in location and may continue to be used to vote your shares in connection with the Special Meeting.

About CytoDyn

CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn filed its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients, and submitted additional FDA requested clinical datasets on May 11, 2020. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at www.cytodyn.com.

https://ml.globenewswire.com/media/3c50d220-d0d1-4cf0-a0c3-087532ed371c/small/cytodynlogo-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.